Intralipid for Repeated Implantation Failure

Does Intralipid Infusion Improve the Implantation Rate in Repeated Implantation Failure: a Randomized Controlled Trial

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01540591

Acronym

Intralipid

Enrollment

200

Registered

2012-02-29

Start date

2012-02-29

Completion date

2014-06-30

Last updated

2016-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Keywords

repeated implantation failure, intralipid

Brief summary

Intralipid infusion can improve outcome in women with recurrent Intracytoplasmic sperm injection ( ICSI) failure due to elevated TH1 cytokine response.

Detailed description

Infertile patients undergoing Intracytoplasmic Sperm Injection (ICSI) cycle with history of repeated implantation failure, intralipid will be given to the intervention group. The primary outcome measure is the clinical pregnancy rate, secondary outcome measures implantation rate, ongoing pregnancy rate, abortion rate.

Interventions

DRUGintralipid

IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test

DRUGSaline

Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Yes

Inclusion criteria

* Infertile patients undergoing ICSI cycle with history of repeated implantation failure

Exclusion criteria

1. Disturbances of normal fat metabolism such as pathologic hyperlipemia 2. Allergic to it; or to eggs, soybean oil, or safflower oil. 3. Severe liver disease, kidney disease, lung disease, anemia, blood clotting disorder. 4. Uterine fibroid, endometrial polyp, endometriosis and hydrosalpinx.

Design outcomes

Primary

Measure	Time frame	Description
clinical pregnancy rate	10 month	pregancy sac with fetal heart activity

Secondary

Measure	Time frame	Description
implantation rate	10 month	the number of gestational sacs divided by the number of embryos transferred
ongoing pregnancy rate	14 month	clinical pregnancy continue after 12 weeks gestational age

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026